Immune Activation and Viral Replication after Vaccination with an Influenza A H1N1 2009 Vaccine in HIV-Infected Children Receiving Antiretroviral Therapy

Table 2

Seroprotection and seroconversion rates against pandemic H1N1 2009.

Immunogenicity	Controller			Noncontroller
	Baseline proportion (%)	After 1st dose proportion (%)	After 2nd dose proportion (%)	Baseline proportion (%)	After 1st dose proportion (%)	After 2nd dose proportion (%)
Seroprotection	14/29 (48.3)	19/29 (65.5)	21/29 (72.4)	5/16 (31.3)	7/16 (43.8)	8/16 (50.0)
Seroconversion	N/A	13/29 (44.8)	16/29 (55.2)	N/A	5/16 (31.3)	5/16 (31.3)

Note: N/A: non applicable.